Back

Long-term real-world effectiveness and tolerability of alirocumab in high-risk patients with uncontrolled ldl-cholesterol

24 April 2026 (08:30 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Secondary Prevention EAPC Premium Access ESC Preventive Cardiology 2026 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Guillermo Villar Ochoa

UNIVERSITY HOSPITAL VIRGEN DE VALME, Seville (Spain)

84 More presentations in this session

Presentation thumbnail
Prediction models for valvular heart disease in the community: a systematic review and meta-analysis
Mr W. Ginks (Leeds, GB)
Abstract Slides
Presentation thumbnail
The prevalence and clinical significance of ecg abnormalities in individuals with a bicuspid aortic valve
Doctor E. Nakou (London, GB)
Abstract Slides
Presentation thumbnail
Arrhythmogenic cardiomyopathy. Prospects for assessing the degree of electrical instability in the damage zone
Professor S. Bondarev (Padua, IT)
Abstract
Presentation thumbnail
Age-stratified predictors of ventricular ectopy in non-ischemic DCM
Mrs N. Hart-Foia (Cluj Napoca, RO)
Abstract Slides
Presentation thumbnail
Cardiopulmonary fitness in patients with a systemic right ventricle: the QUALISYSTEMIC study
Doctor M. Audie (Bordeaux, FR)
Abstract Slides

Access the full session

Session thumbnail
Poster session (2)

The Event

Event poster

ESC Preventive Cardiology 2026

24 April 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment
2 September 2019
thumbnail
Congress Presentation
Blood pressure and LDL-cholesterol control in patients with primary hypertension is far from optimal: results from a large observational, multicentric, prospective study
1 September 2019
thumbnail
Webinar
How to treat patients with borderline dyslipidemia
8 February 2023
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in reducing LDL cholesterol and triglycerides: real-life experience in a third level hospital: a descriptive, bivariate, and multivariate analysis.
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources